GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » Cyclically Adjusted Revenue per Share

HRTX (Heron Therapeutics) Cyclically Adjusted Revenue per Share : $1.15 (As of Dec. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Heron Therapeutics's adjusted revenue per share for the three months ended in Dec. 2024 was $0.266. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.15 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Heron Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 0.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Heron Therapeutics was 19.10% per year. The lowest was -29.50% per year. And the median was 2.60% per year.

As of today (2025-04-30), Heron Therapeutics's current stock price is $2.42. Heron Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $1.15. Heron Therapeutics's Cyclically Adjusted PS Ratio of today is 2.10.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Heron Therapeutics was 65.63. The lowest was 0.50. And the median was 14.74.


Heron Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Heron Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Cyclically Adjusted Revenue per Share Chart

Heron Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 1.09 1.14 1.14 1.15

Heron Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 1.16 1.16 1.15 1.15

Competitive Comparison of Heron Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Heron Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Heron Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Heron Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.266/133.1571*133.1571
=0.266

Current CPI (Dec. 2024) = 133.1571.

Heron Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.033 101.863 0.043
201703 0.072 102.862 0.093
201706 0.158 103.349 0.204
201709 0.158 104.136 0.202
201712 0.174 104.011 0.223
201803 0.179 105.290 0.226
201806 0.240 106.317 0.301
201809 0.254 106.507 0.318
201812 0.369 105.998 0.464
201903 0.403 107.251 0.500
201906 0.461 108.070 0.568
201909 0.533 108.329 0.655
201912 0.393 108.420 0.483
202003 0.281 108.902 0.344
202006 0.250 108.767 0.306
202009 0.220 109.815 0.267
202012 0.226 109.897 0.274
202103 0.219 111.754 0.261
202106 0.228 114.631 0.265
202109 0.228 115.734 0.262
202112 0.202 117.630 0.229
202203 0.230 121.301 0.252
202206 0.270 125.017 0.288
202209 0.238 125.227 0.253
202212 0.252 125.222 0.268
202303 0.248 127.348 0.259
202306 0.265 128.729 0.274
202309 0.217 129.860 0.223
202312 0.226 129.419 0.233
202403 0.229 131.776 0.231
202406 0.237 132.554 0.238
202409 0.215 133.029 0.215
202412 0.266 133.157 0.266

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Heron Therapeutics  (NAS:HRTX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Heron Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.42/1.15
=2.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Heron Therapeutics was 65.63. The lowest was 0.50. And the median was 14.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Heron Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Heron Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Executives
William P Forbes officer: EVP, Chief Development Officer C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte officer: EVP, Chief Financial Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen other: See Footnote 1 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp other: See Footnote 1 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman other: See Footnote 2 FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian director RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121